Chimeric Antigen Receptor Therapy
- PMID: 29972754
- PMCID: PMC7433347
- DOI: 10.1056/NEJMra1706169
Chimeric Antigen Receptor Therapy
Figures
![Figure 1.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/7433347/bin/nihms-1614319-f0001.gif)
![Figure 2.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/7433347/bin/nihms-1614319-f0002.gif)
Comment in
-
A Look Forward - The Frontiers in Medicine Series.N Engl J Med. 2018 Jul 5;379(1):85-86. doi: 10.1056/NEJMe1806084. N Engl J Med. 2018. PMID: 29972760 No abstract available.
Similar articles
-
Functional design of chimeric T-cell antigen receptors for adoptive immunotherapy of cancer: architecture and outcomes.Anticancer Res. 2012 Jun;32(6):2377-83. Anticancer Res. 2012. PMID: 22641678 Review.
-
CAR therapy: the CD19 paradigm.J Clin Invest. 2015 Sep;125(9):3392-400. doi: 10.1172/JCI80010. Epub 2015 Sep 1. J Clin Invest. 2015. PMID: 26325036 Free PMC article. Review.
-
What CAR Will Win the CD19 Race?Mol Cancer Ther. 2019 Mar;18(3):498-506. doi: 10.1158/1535-7163.MCT-18-1070. Mol Cancer Ther. 2019. PMID: 30824581 Review.
-
Chimaeric antigen receptor T-cell therapy for tumour immunotherapy.Biosci Rep. 2017 Jan 27;37(1):BSR20160332. doi: 10.1042/BSR20160332. Print 2017 Feb 28. Biosci Rep. 2017. PMID: 28053197 Free PMC article. Review.
-
Retargeting CD19 Chimeric Antigen Receptor T Cells via Engineered CD19-Fusion Proteins.Mol Pharm. 2019 Aug 5;16(8):3544-3558. doi: 10.1021/acs.molpharmaceut.9b00418. Epub 2019 Jul 15. Mol Pharm. 2019. PMID: 31242389
Cited by
-
T cell dysfunction and therapeutic intervention in cancer.Nat Immunol. 2024 Jul 18. doi: 10.1038/s41590-024-01896-9. Online ahead of print. Nat Immunol. 2024. PMID: 39025962 Review.
-
Chimeric antigen receptor T cell therapy for autoimmune disease.Nat Rev Immunol. 2024 Jun 3. doi: 10.1038/s41577-024-01035-3. Online ahead of print. Nat Rev Immunol. 2024. PMID: 38831163 Review.
-
Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in hematologic malignancies: a living systematic review (protocol).Open Res Eur. 2024 May 21;2:38. doi: 10.12688/openreseurope.14390.2. eCollection 2022. Open Res Eur. 2024. PMID: 38827275 Free PMC article.
-
Legacy of the discovery of the T-cell receptor: 40 years of shaping basic immunology and translational work to develop novel therapies.Cell Mol Immunol. 2024 Jul;21(7):790-797. doi: 10.1038/s41423-024-01168-4. Epub 2024 May 31. Cell Mol Immunol. 2024. PMID: 38822079 Free PMC article. No abstract available.
-
Engineered CAR-T cells targeting the non-functional P2X purinoceptor 7 (P2X7) receptor as a novel treatment for ovarian cancer.Clin Transl Immunology. 2024 May 23;13(5):e1512. doi: 10.1002/cti2.1512. eCollection 2024. Clin Transl Immunology. 2024. PMID: 38800555 Free PMC article.
References
-
- Hoos A. Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov 2016;15:235–47. - PubMed
-
- Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356:1928–43. - PubMed
-
- Billingham RE, Brent L, Medawar PB. Quantitative studies on tissue transplantation immunity. II. The origin, strength and duration of actively and adoptively acquired immunity. Proc R Soc Lond B Biol Sci 1954;143:58–80. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources